期刊文献+

中医药防治乳腺癌内分泌治疗不良反应探讨 被引量:1

下载PDF
导出
摘要 目的:对中医药防治乳腺癌內分泌治疗的不良反应进行相关的探讨。方法选取我院2012年5月~2013年5月内分泌治疗乳腺癌不良患者100例,将其分为两组,对照组30例,使用口服TAM的方法治疗,治疗组70例,使用口服TAM,同时,针对不同反应和症状的患者采用不同的中医药进行治疗,对两组患者不良反应的治疗效果进行比较,进而对中医药防治乳腺癌內分泌治疗不良反应的情况进行探讨。结果治疗组治疗的有效率为94.3%,对照组治疗的有效率为73.3%,治疗组治疗不良反应的效果明显优于对照组。<0.05,表示差异具有统计学意义。结论采用中医药辩证的分证论治方法来防治乳腺癌内分泌治疗不良反应具有非常好的疗效。
出处 《医学信息(医学与计算机应用)》 2014年第30期322-322,共1页 Medical Information
  • 相关文献

参考文献3

二级参考文献31

  • 1陈琳,武正炎.NSABP乳腺癌临床试验的最新成果和应用前景[J].实用临床医药杂志,2006,10(2):12-17. 被引量:5
  • 2No authors listed.Tamoxifen for early breast cancer:an overview of the randomised trials.Early Breast Cancer Trialists' Collaborative Group[J].Lancet,1998,351(9114):1451-1467. 被引量:1
  • 3Baum M,Budzar AU,Cuzick J,et al.Anastrozole alone or in combina-tion with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial[J].Lancet,2002,359(9324):2131-2139. 被引量:1
  • 4Baum M,Buzdar A,Cuzick J,et al.Anastrozole alone or in combina-tion with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC(Arimidex,Tamoxifen Alone or in Combination)trial efficacy and safety update analyses[J].Cancer,2003,98(9):1802-1810. 被引量:1
  • 5Dowsett M,Cuzick J,Wale C,et al.Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status:an hypothesis-generating study[J].J Clin Oncol,2005,23(30):7512-7517. 被引量:1
  • 6Sestak I,Cuzick J,Sapunar F,et al.Risk factors for joint symptoms in patients enrolled in the ATAC trial:a retrospective,exploratory analy-sis[J].Lancet Oncol,2008,9(9):866-872. 被引量:1
  • 7Kvinnsland S,Anker G,Dirix LY,et al.High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment[J].Eur J Cancer,2000,36(8):976-982. 被引量:1
  • 8Lonning PE,Bajetta E,Murray R,et al.Activity of exemestane in me-tastatic breast cancer after failure of nonsteroidal aromatase inhibitors:a phase Ⅱ trial[J].J Clin Oncol,2000,18(11):2234-2244. 被引量:1
  • 9Paridaens R,Dirix L,Lohrisch C,et al.Mature results of a randomized phase Ⅱ multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer[J].Ann Oncol,2003,14(9):1391-1398. 被引量:1
  • 10Malay G,Dirix L,Biganzoli L,et al.The effect of exemestane on ser-um lipid rofile in postmenopausal women with metastatic breast canc-er:a companion study to EORTC Trial 10951,'Randomized phaseⅡ study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'[J].Ann Oncol,2004,15(2):211-217. 被引量:1

共引文献28

同被引文献14

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部